The contraindication population for Conafenib mainly includes BRAF wild-type tumor patients and patients with severe liver function impairment, and its use should strictly follow clinical guidelines to avoid potential risks. The following will explain from two aspects: contraindications and precautions for special populations.

1. Prohibited population of Conafenib

1.1 BRAF wild-type tumor patients

Conafenib is only suitable for patients with BRAFV600E or V600K mutations confirmed by FDA approved testing. The use of wild-type BRAF in cancer patients may lead to tumor promoting effects, so the mutation status must be confirmed through genetic testing before treatment.

1.2 Patients with severe liver function impairment

Patients with moderate or severe liver function impairment (Child Pugh B or C grade) lack safety and efficacy data and are not recommended for use. Patients with mild liver function impairment (Child Pugh Class A) do not require dose adjustment, but close monitoring of liver function indicators is still necessary.

2. Medication instructions for relevant populations

2.1 Monitoring requirements for patients with abnormal liver function

Before treatment, a baseline liver function test is required, and monthly follow-up is required during the treatment period. When AST/ALT levels increase, graded treatment is required: Grade 2 requires dose observation, Grade 3-4 requires temporary or permanent discontinuation of medication, and specific adjustment plans need to be combined with clinical indications.

2.2 Precautions for other high-risk groups

Pregnant women should avoid breastfeeding (which may cause harm to the fetus), and lactating women should stop breastfeeding. Although elderly patients do not need to adjust their dosage, they should pay attention to the situation of concomitant medication. Patients with severe renal impairment also lack medication data and require careful evaluation.